Today represents a significant milestone for Triveni as we close a $115 Million Series B Financing – led by Goldman Sachs Alternatives – to expand our pipeline of novel therapies for I&I disorders like #atopicdermatitis. Read more: https://bit.ly/4epr5GN Learn more about Triveni: https://triveni.bio/ #biotech #precisionmedicine #immunology #inflammation
关于我们
Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact. To learn more, visit www.triveni.bio.
- 网站
-
https://www.triveni.bio
Triveni Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Watertown，MA
- 类型
- 私人持股
地点
-
主要
获取路线
99 Coolidge Avenue
US，MA，Watertown，02472
Triveni Bio员工
动态
-
Today, Triveni Bio's senior management participated in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit, where they provided key updates on the company's lead program, TRIV-509, along with other pipeline program updates.?Watch a replay of the webcasted presentation here: https://lnkd.in/ejau5eQp
-
Happy to share that our redesigned website is live! Explore our team, culture, science and pipeline at the new www.triveni.bio.
-
We are thrilled to welcome Dr. Bhaskar Srivastava, M.D., Ph.D., Triveni’s new Chief Medical Officer! He arrives at a key moment of growth and evolution for the company as we advance our lead program, TRIV-509, into the clinic in the first half of 2025. Dr. Srivastava’s extensive training as a dermatologist and immunologist will further our goal of driving much needed innovation for I&I diseases. Learn more about today’s announcement here: https://bit.ly/3KHxJLC #Inflammation #Immunology #Dermatology #Innovation #Biotech
-
Exciting news from Triveni Bio after a busy week! Jennifer Dovey, our CSO, delivered an oral presentation on TRIV-509 at the Society for Investigative Dermatology’s 2024 Annual Meeting. The presentation focused on the promising results of TRIV-509 in atopic dermatitis models, demonstrating its ability to ameliorate barrier dysfunction, inflammation, and itch. Jennifer and Eva Asp, VP of Biology, also presented a poster covering the oral data in detail. Brantley Herrin, VP of Biologics, and Ye Tang, Sr. Scientist, Biologics, presented a poster on TRIV-509, our dual-specific antibody targeting KLK5 and KLK7 proteases at the PEGS 2024 Essential Protein & Antibody Engineering Summit. The poster highlighted TRIV-509's high-affinity binding at the active sites of each protease, effectively inhibiting the proteolytic activity of both. These presentations showcase the potential of TRIV-509 as a novel treatment for atopic dermatitis patients and beyond.?
-
-
We are thrilled to welcome Jeff Albers as our new Board Chair and Allison Luo, MD to our Board of Directors, who each bring an impressive wealth of operational experience and direct knowledge of the I&I landscape. Jeff and Allison's appointment marks a pivotal moment of growth for the company, and we look forward to their ongoing support as we advance TRIV-509 into the clinic in 2025 and build out Triveni’s novel antibody pipeline for multiple diseases with high medical need. Read more: https://lnkd.in/eETQ6GG8 #biotech #leadership #immunology #inflammation #precisionmedicine?